{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T10:17:40Z","timestamp":1696673860155},"reference-count":32,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T00:00:00Z","timestamp":1488758400000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1AI106701","HHSN272201500006C","D43TW010313","K08MH098794"],"award-info":[{"award-number":["UM1AI106701","HHSN272201500006C","D43TW010313","K08MH098794"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There are many factors that can affect the pharmacokinetics (PK) of drugs. Pathophysiological changes from disease states can alter the mechanisms that control the PK of antiretrovirals (ARVs), direct\u2010acting antivirals (DAAs), and addiction treatment medications. Drug\u2013drug interaction pathways of certain ARVs and DAAs can be very complex, with agents being substrates, inhibitors, or inducers of multiple metabolic and transporter pathways. Buprenorphine and methadone may be used in HIV\u2010 and hepatitis C virus (HCV)\u2013infected patients and may also be affected by drug interactions. Current research is focused on novel PK analyses, which aim to describe the PK of agents within organs that host the infection of interest, such as within hepatocytes during treatment for HCV. Modeling techniques allow for the prediction of drug PK in specific organs and the plasma compartment. This review will provide a summary of these areas while exploring PK considerations for ARVs, DAAs, and addiction treatment medications.<\/jats:p>","DOI":"10.1002\/cpdd.313","type":"journal-article","created":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T15:25:23Z","timestamp":1488813923000},"page":"135-139","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct\u2010Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications"],"prefix":"10.1002","volume":"6","author":[{"given":"Cindy J.","family":"Bednasz","sequence":"first","affiliation":[{"name":"AIDS Clinical Trials Group Pharmacology Specialty Laboratory, New York State Center of Excellence in Bioinformatics and Life Sciences, School of Pharmacy and Pharmaceutical Sciences University at Buffalo  Buffalo NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles S.","family":"Venuto","sequence":"additional","affiliation":[{"name":"AIDS Clinical Trials Group Pharmacology Specialty Laboratory, New York State Center of Excellence in Bioinformatics and Life Sciences, School of Pharmacy and Pharmaceutical Sciences University at Buffalo  Buffalo NY USA"},{"name":"Center for Human Experimental Therapeutics University of Rochester  Rochester NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Ma","sequence":"additional","affiliation":[{"name":"AIDS Clinical Trials Group Pharmacology Specialty Laboratory, New York State Center of Excellence in Bioinformatics and Life Sciences, School of Pharmacy and Pharmaceutical Sciences University at Buffalo  Buffalo NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gene D.","family":"Morse","sequence":"additional","affiliation":[{"name":"AIDS Clinical Trials Group Pharmacology Specialty Laboratory, New York State Center of Excellence in Bioinformatics and Life Sciences, School of Pharmacy and Pharmaceutical Sciences University at Buffalo  Buffalo NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,3,6]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"MenonR BadriP DasU et\u00a0al.Drug\u2010drug interactions with direct\u2010acting antiviral combination therapy of ABT\u2010450\/r ombitasvir and dasabuvir.54th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 5\u20139 2014; Washington DC.http:\/\/www.natap.org\/2014\/ICAAC\/ICAAC_19.htm. Accessed November 20 2015."},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00097-14"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.25.190"},{"key":"e_1_2_11_5_1","unstructured":"U.S. Food and Drug Administration.Drug development and drug interactions: table of substrates inhibitors and inducers.http:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/DrugInteractionsLabeling\/ucm093664.htm.Accessed November 5 2014."},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02278-15"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.109.031732"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.25.190"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v9.i2.359"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(97)00040-9"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/11592660-000000000-00000"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.2.643-649.2005"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.8.1835"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.2217\/fvl.15.64"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.03.025"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.146647"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2014.24"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2958"},{"key":"e_1_2_11_19_1","unstructured":"AASLD\/IDSA\/IAS\u2013USA.Recommendations for testing managing and treating hepatitis C.http:\/\/www.hcvguidelines.org. Accessed November 20 2015."},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31821d3adb"},{"key":"e_1_2_11_21_1","first-page":"818","article-title":"Human buprenorphine N\u2010dealkylation is catalyzed by cytochrome P450 3A4","volume":"26","author":"Kobayashi K","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2010.00628.x"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-010-0048-2"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2007.06.007"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1086\/429503"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1086\/376907"},{"key":"e_1_2_11_27_1","unstructured":"U.S. Department of Health and Human Services. Food and Drug Administration Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). Guidance for Industry. Population Pharmacokinetics. February 1999."},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1991.tb03971.x"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.41"},{"key":"e_1_2_11_30_1","unstructured":"JameiM.An Introduction to: In Vitro \u2010 In Vivo Extrapolation (IVIVE). The University of Greenwich 29th Oct 2009.http:\/\/www.slideshare.net\/mjamei\/an-introduction-toin-vitroin-vivoextrapolation-ivive. Accessed November 20 2015."},{"key":"e_1_2_11_31_1","unstructured":"U.S. National Library of Medicine. Genetics Home Reference.http:\/\/ghr.nlm.nih.gov\/handbook\/genomicresearch\/pharmacogenomics. Accessed November 11 2015."},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2013.30"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.14.19"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpdd.313","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.313","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T18:21:47Z","timestamp":1696616507000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1002\/cpdd.313"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.313","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3]]}}}